Patents Examined by Carla J. Myers
  • Cancer diagnosis method
    Patent number: 7163789
    Abstract: The invention concerns a method for the diagnosis and/or the follow up of the evolution of cancer comprising the analysis of the RNA components of the telomerase enzyme present in the plasma or serum of the blood.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: January 16, 2007
    Inventors: Xu Qi Chen, Maurice Stroun, Philippe Anker
  • Human ribonucleotide reductase M2 subunit
    Patent number: 7157570
    Abstract: An isolated nucleic acid containing a human ribonucleotide reductase M2 subunit promoter sequence or genomic sequence. Also disclosed are methods of determining whether a subject is suffering from or at risk for developing a cell proliferation-associated disorder, identifying a compound for treating a cell proliferation-associated disorder, treating a cell proliferation-associated disorder, and developing a procedure for treating a cell proliferation-associated disorder.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: January 2, 2007
    Inventor: Yun Yen
  • Reagent kit for determining specific nucleotide variations
    Patent number: 7132235
    Abstract: Detection of variable nucleotide(s) is based on primer extension and incorporation of detectable nucleoside triphosphates. By selecting the detection step primers from the region immediately adjacent to the variable nucleotide, this variation can be detected after incorporation of as few as one nucleoside triphosphate. Labelled nucleoside triphosphates matching the variable nucleotide are added and the incorporation of a label into the detection step primer is measured. The selection of the detection step primer is important to the method according to this invention and is dependent on the nucleotide sequence of interest. The detection step primers are preferably selected so as to span the region immediately toward the 3? end from the variable nucleotide to be detected. The detection step primers can also be complementary to a sequence beginning several nucleotides removed from the variable nucleotide.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 7, 2006
    Assignee: Orchid Cellmark Inc.
    Inventors: Hans E. Söderlund, Anne-Christine Syvanen
  • Sequences for the detection of
    Patent number: 7125661
    Abstract: An isolated nucleic acid molecule comprising a nucleotide sequence encoding a transcriptional enhancer of cytochrome P450 (P450) CYP3A4 production or expression is disclosed, as are uses of the nucleic acid molecule for screening compounds for xenobiotic induction of CYP3A4 expression in cells and animals.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: October 24, 2006
    Assignee: The University of Sydney
    Inventors: Peter Richard Reeves, Lei Wang
  • Methods to screen peptide libraries using minicell display
    Patent number: 7125679
    Abstract: A minicell display method has been developed which has significant advantages for screening peptide libraries for candidates that can bind and effectively modulate a particular biological process. The method, based on the small, anucleate minicell, has increased versatility in generating unique sequences to screen as well as increasing the size of the peptides to be screened. In vivo mutagenesis, at the level of protein synthesis, as well as DNA replication, increases diversification of the library to be screened and therefore substantially increases the number of potential peptides that can modulate a particular biological response or mechanism.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: October 24, 2006
    Assignee: Children's Medical Center Corporation
    Inventor: Samy Ashkar
  • Methods for determining the risk of developing asthma characterized by bronchial hyperresponsiveness
    Patent number: 7122311
    Abstract: The invention relates to the use of an asthma-associated gene, designated AAGA, the protein molecule encoded by AAGA and related molecules in diagnostic and prognostic screening of patient populations, to polymorphisms in AAGA, and to the use of the protein encoded by AAGA or a variant thereof as a therapeutic target.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: October 17, 2006
    Assignees: Novartis AG, Wake Forest University Health Sciences, Rijksuniversiteit Groningen
    Inventors: Paul Andrew Whittaker, Deborah Alexis Meyers, Dirkje Sjoukje Postma, Eugene Roland Bleecker
  • Methods for diagnosing severe systemic lupus erythematosus
    Patent number: 7118865
    Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: October 10, 2006
    Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical Research
    Inventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
  • Method for detecting a propensity of an individual to respond effectively to treatment of interferon-? and ribavirin combined therapy
    Patent number: 7108978
    Abstract: It is provided isolated polynucleotides that include sequences from genomic region around the gene CD 81. The polynucleotides include polymorphisms associated with treatment response of HCV patients to interferon-? and ribavirin combined therapy and are useful as the probes in screening for patients who will response to interferon-? and ribavirin combined therapy. It is further provided linkage disequilibrium structure of the CD81 gene and haplotype information within a particular LD block, which can be used for prediction of the treatment outcome of the interferon-? and ribavirin combined therapy on HCV patients.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: September 19, 2006
    Assignee: Vita Genomics, Inc.
    Inventors: Jui-Lin Chen, Yuchi Hwang, Min-Pey Ding, Wen-Pi Chu, Shu-Ching Wang, Kuei-Ling Belinda Chen, Wan-Lin Yao, Kuang-Den Chen, Ding-Shinn Chen, Pei-Jer Chen, Ming-Yang Lai
  • Atlastin
    Patent number: 7108975
    Abstract: The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: September 19, 2006
    Assignee: Regents of the University of Michigan
    Inventors: John K. Fink, Xinping Zhao
  • High-throughput glutathione S-transferase polymorphic allele assay design
    Patent number: 7083923
    Abstract: A high-throughput assay for characterizing a subject's genetic makeup is disclosed. Specifically a high-throughput assay utilizing PCR is disclosed that permits the rapid and accurate characterization of a subject's inherited alleles of the polymorphic glutathione S-transferase (GST) genes GSTM1, GSTM3, GSTP1, and GSTT1. This method allows detection of the specific alleles inherited, including the gene dosage of GSTM1 and GSTT1 while not requiring restriction endonuclease digestion of the PCR products in order to detect length differences. Further, the method allows all analyses to be performed simultaneously in the same gel lane, thus further adding efficiency and cost-effectiveness.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: August 1, 2006
    Assignee: University of Utah Research Foundation
    Inventors: Charles Keller, Linda Ballard, Richard Lemmons, Francis Ali-Osman
  • Method to determine the risk for side effects of an SSRI treatment in a person
    Patent number: 7083921
    Abstract: A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: August 1, 2006
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Greer M. Murphy, Alan F. Schatzberg
  • CIDE-B polypeptides
    Patent number: 7081515
    Abstract: The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: July 25, 2006
    Assignee: Serono Genetics Institute S.A.
    Inventor: Lydie Bougueleret
  • Serine carboxypeptidase hx (SCPhx) and compositions thereof
    Patent number: 7074571
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: July 11, 2006
    Assignee: Serono Genetics Institute SA
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Genetic markers for improved disease resistance in animals (BPI)
    Patent number: 7070929
    Abstract: A method for determining improved disease resistance in animals is disclosed. The method assays for a novel genetic alleles of the BPI gene of the animal. The alleles are correlated with superior disease resistance. Novel nucleotide sequences, assays and primers are disclosed for the methods of the invention.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: July 4, 2006
    Assignees: Iowa State University Research Foundation, Inc., Pig Inprovement Company UK Limited, The United States of America as represented by the Secretary of Agriculture
    Inventors: Christopher K. Tuggle, Thomas J. Stabel, Xianwei Shi, Martha A. Mellencamp
  • Methods for the detection, identification, and/or enumeration of yeast, particularly in wine
    Patent number: 7060432
    Abstract: This invention is related to novel probes, probe sets, methods and kits pertaining to the detection, identification and/or quantitation of yeasts and particularly Dekkera bruxellensis (a.k.a. Brettanomyces) an organism that spoils wine. Preferred probes for the detection of one or more species of the Dekkera/Brettanomyces genus comprise a probing nucleobase sequence, at least a portion of which is selected from the group consisting of: AGC-GGG-TCT-ATT-AGA (Seq. ID No. 1); CCA-GGT-GAG-GGT-CGC (Seq. ID No. 2); CGG-TTG-CCC-GAT-TTC (Seq. ID No. 3); TCG-CCT-TCC-TCC-TCT (Seq. ID No. 4); CGG-TCT-CCA-GCG-ATT (Seq. ID No. 5); CAC-AAG-ATG-TCC-GCG (Seq. ID No. 6); GCG-GGC-ACT-AAT-TGA (Seq. ID No. 7); CAT-CCA-CGA-GGA-ACG (Seq. ID No. 8); GTG-TAA-ACC-AGG-TGC (Seq. ID No. 9); ATG-GCT-CCC-AGA-ACC (Seq. ID No. 10) and GAC-AGA-ATC-GAA-GGG (Seq. ID No. 11).
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: June 13, 2006
    Assignee: Applera Corporation
    Inventors: Jens J. Hyldig-Nielsen, Heather P. O'Keefe, Henrik Stender
  • Binary probe and clamp composition
    Patent number: 7057025
    Abstract: Binary probe and clamp compositions conduct methods for target hybridization detection. Where the probe is a substrate for exonuclease cleavage, the composition provides quantitation and detection of PCR products, by real-time and end-point measurements. Where the probe is an amplification primer, the composition provides an improved method for labelling and detection of PCR products. Probes and clamps may be labelled with fluorescent dyes, quenchers, hybridization-stabilizing moieties, chemiluminescent dyes, and affinity ligands. Clamps may be nucleic acid analogs, such as 2-aminoethylglycine PNA.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: June 6, 2006
    Assignee: Applera Corporation
    Inventors: Kenneth J. Livak, Michael Egholm, Michael W. Hunkapiller
  • Methods for diagnosis of lung cancer
    Patent number: 7049063
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: May 23, 2006
    Assignee: Corixa Corporation
    Inventors: Tongtong Wang, Liqun Fan, Michael D. Kalos, Chaitanya S. Bangur, Nancy A. Hosken, Gary R. Fanger, Samuel X. Li, Aijun Wang, Yasir A. W. Skeiky, Robert A. Henderson, Patricia D. McNeill, Neil Fanger
  • Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state
    Patent number: 7049072
    Abstract: Pluri-differentiated human mesenchymal progenitor cells (MPCs) are isolated. A method isolates and purifies human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: May 23, 2006
    Assignee: University of South Florida
    Inventor: Beerelli Seshi
  • Method and marker for identification of pre-malignancy and malignancy and therapeutic intervention
    Patent number: 7045292
    Abstract: There is provided a method for identifying pre-malignancy, malignancy, and degree of pre-malignancy and malignancy of a cell by detecting extrachromosomal and intrachromosomal gene amplification. Also provided is a marker for the identification of pre-malignancy, malignancy, and degree of pre-malignancy and malignancy of a cell containing extrachromosomal and intrachromosomal gene amplification of a gene. A diagnostic tool for the diagnosis and prognosis or cervical cancer containing extrachromosomal and intrachromosomal gene amplification of a gene.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: May 16, 2006
    Assignees: University of Manitoba, Cancercare Manitoba
    Inventor: Sabine Mai
  • Method for diagnosing GH deficiency
    Patent number: 7041450
    Abstract: The present invention relates to a method and kit for diagnosing GH (growth hormone) deficiency, in particular isolated growth hormone deficiency II (IGHD II). The method comprises the steps of analysing the missense mutation G6191 to T in exon 4 of GH-1 which changes valine 110 to phenylalanine.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: May 9, 2006
    Assignee: Pharmacia AB
    Inventor: Michael Ranke